EDIT Q3 FY2026 earnings: results, stock reaction and implied move

Reported results

Net loss attributable to common stockholders for the three months ended September 30, 2026, was $23.4 million, or $0.15 per share, compared to $25.1 million, or $0.28 per share, for the same period in 2025.
Collaboration and other research and development revenues were $10.4 million for the three months ended September 30, 2026, compared to $7.5 million for the same period in 2025.
Research and development expenses were $21.2 million for the three months ended September 30, 2026, compared to $19.8 million for the same period in 2025.
General and administrative expenses were $13.5 million for the three months ended September 30, 2026, compared to $12.3 million for the same period in 2025.
Cash, cash equivalents, and marketable securities as of September 30, 2026, were $190.2 million compared to $146.6 million as of December 31, 2025.

Editas Medicine expects that its existing cash, cash equivalents, and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2028.

The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.